| Chai Yu-xiao,Han Yu,Wang Bing,Zhang Yi,Qu Xing-long. Clinical study of docetaxel plus S-1 as neoadjuvant therapy for advanced gastric cancer. Oncol Transl Med, 2016, 2: 80-83. |
| 多西他赛联合替吉奥方案治疗进展期胃癌新辅助化疗的疗效观察 |
| Clinical study of docetaxel plus S-1 as neoadjuvant therapy for advanced gastric cancer |
| Received:June 06, 2015 Revised:April 11, 2016 |
| DOI：10.1007/s10330-015-0099-3 |
| 中文关键词: 进展期胃癌；新辅助化疗；根治性手术；治疗效果 |
| 英文关键词: advanced gastric cancer; neoadjuvant chemotherapy; surgery; curative operation |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Chai Yu-xiao | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | chaiyuxiao@163.com | | Han Yu* | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | arowana2010@163.com | | Wang Bing | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | 1179514384@qq.com | | Zhang Yi | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | ansonzhang0226@hotmail.com | | Qu Xing-long | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | quxl681@163.com |
|
| Hits: 8395 |
| Download times: 10729 |
| 中文摘要: |
| 目的：观察多西他赛联合替吉奥方案治疗进展期胃癌新辅助化疗的临床疗效、不良反应及术后并发症。方法 于2013 年7 月至 2014年12 月间，明确诊断的30 例进展期胃癌患者入组本次临床研究。新辅助化疗方案为：多西他赛75mg/m2第1天，替吉奥60mg/m2第1～14天，每3 周为一个周期，2个疗程后评估新辅助化疗的疗效并观察用药后的毒副反应。结果 新辅助化疗后入组患者影像学评估，完全缓解（CR）2例，部分缓解（PR）21例，稳定（SD）7例，进展（PD）0例，临床有效率（CR +PR）为76.6%（23/30）。均进行了手术， 86.6%的患者(26/30)获得根治性手术，其中88.8%的患者(23/26)接受了D2淋巴结清扫术，剖腹探查率为13.3%（4/30），无手术死亡病例，新辅助化疗的毒副反应主要为白细胞减少、腹泻、恶心、呕吐等。结论 多西他赛联合替吉奥方案在进展期胃癌患者新辅助化疗中疗效确切，安全，不良反应可以耐受。 |
| 英文摘要: |
| Objective To evaluate the efficacy, toxicity, and operative complications of docetaxel in combination with
S-1 for treating patients with advanced gastric cancer.
Methods From July 2013 to December 2014, 30 patients with advanced gastric cancer were treated with
i.v. docetaxel 75 mg/m2 on day 1 and oral S-1 60 mg/m2 bid on days 1–14 every 3 weeks. The efficacy and
toxicity were evaluated after two chemotherapy cycles.
Results The overall treatment response (complete response [CR] partial response [PR]) was 76.6%
(23/30), CR was 6.7% (2/30), PR was 70.0% (21/30), SD was 23.3% (7/30), and progression disease was
0% (0/30). All patients were treated surgically. Twenty-six patients received radical surgery; of them, 23
received D2 lymph node dissection. The other four patients received exploratory celiotomy. No patients died
in the group, and the adverse reactions included neutropenia, diarrhea, nausea, and vomiting.
Conclusion Docetaxel/S-1 combination is highly active, safe, and well tolerated in patients with advanced
gastric cancer. Further investigations in randomized studies are warranted. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|